Tiffany Rentz
Acute Care · Huntsville, ALNPI 1326706383
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,647 of the $10,575 with a category attached, or 81.8%. 30 manufacturers reported payments, led by Boston Scientific at 33.0% of the total. 2025 is the largest year on record at $3,940, more than ten times the $212 reported in 2021. Among acute care clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$971
- Biosense Webster, Inc.$777
- E.r. Squibb & Sons, L.L.C.$657
- Regeneron Healthcare Solutions, Inc.$483
- Johnson & Johnson$440
- plus $4K from 24 others
What the payments were for
- Travel & lodging$1,91018%
- Food & beverage$8,64782%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $3,490 |
| Abbott | 34 | $971 |
| Biosense Webster, Inc. | 15 | $777 |
| E.r. Squibb & Sons, L.L.C. | 21 | $657 |
| Regeneron Healthcare Solutions, Inc. | 19 | $483 |
| Johnson & Johnson | 17 | $440 |
| Pfizer | 21 | $406 |
| Boehringer Ingelheim | 17 | $406 |
| Amgen | 19 | $392 |
| AstraZeneca | 13 | $380 |
| Sanofi-aventis U.S. LLC | 17 | $324 |
| Bayer | 6 | $240 |
| Merck | 11 | $229 |
| Novo Nordisk | 4 | $191 |
| Alnylam Pharmaceuticals Inc. | 5 | $190 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $146 |
| Medtronic | 3 | $128 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Inspire Medical Systems, Inc. | 5 | $123 |
| Esperion Therapeutics, Inc. | 5 | $98 |
| Scpharmaceuticals Inc. | 4 | $70 |
| Atricure, Inc. | 1 | $69 |
| Novartis | 2 | $45 |
| Convatec Inc. | 2 | $44 |
| Heartflow, Inc. | 2 | $40 |
| United Therapeutics Corporation | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,575 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $324,082 |
| MultaqDronedarone Hcl | 27 | $41,608 |
| EntrestoSacubitril/Valsartan | 19 | $29,905 |
| XareltoRivaroxaban | 29 | $28,592 |
| Flecainide Acetate | 146 | $8,522 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $5,273 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 72 | $3,930 |
| Dofetilide | 22 | $3,629 |
| Metoprolol Succinate | 125 | $1,938 |
| Amiodarone Hcl | 66 | $1,460 |
| SotalolSotalol Hcl | 56 | $1,234 |
| Digoxin | 12 | $469 |
| Carvedilol | 50 | $440 |
| ClopidogrelClopidogrel Bisulfate | 13 | $330 |
| Atenolol | 17 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $406 | $324,082323 claims |
| Sanofi-aventis U.S. LLCMultaq | $324 | $41,60827 claims |
| NovartisEntresto | $45 | $29,90519 claims |
| Johnson & JohnsonXarelto | $440 | $28,59229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.
Other acute care in Huntsville
- April KlarHuntsville$13K
- Stephanie TateHuntsville$13K
- Kelly VazquezHuntsville$12K
- Summer SlaterHuntsville$12K
- Britanie MooreHuntsville$9K
- Trey WilsonHuntsville$8K
- Esther HambrickHuntsville$8K
- Jessica BurkeenHuntsville$8K
- Alyssa EzellHuntsville$8K
- Ashley WrightHuntsville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.